Norgine B.V.
Norgine B.V., a leading European pharmaceutical company headquartered in the Netherlands, has been at the forefront of healthcare innovation since its founding in 1906. With a strong presence across Europe and a commitment to improving patient outcomes, Norgine focuses on developing and commercialising high-quality products in the fields of gastroenterology, hepatology, and supportive care. Renowned for its unique formulations and patient-centric approach, Norgine offers a range of core products, including bowel preparation solutions and treatments for liver disease. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of innovative therapies, solidifying its position as a trusted name in the pharmaceutical industry. Norgine's dedication to excellence and patient care continues to drive its success in a competitive market.
DitchCarbon Score
How does Norgine B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Norgine B.V.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Norgine B.V.'s reported carbon emissions
Norgine B.V., headquartered in the Netherlands (NL), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Norgine B.V. does not inherit any emissions data from a parent or related organization, nor does it participate in any recognised climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the pharmaceutical industry, where Norgine operates, companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific commitments or data, Norgine's current climate impact and future goals remain unclear.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Norgine B.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
